Anti–TNF-α Use During the Third Trimester of Pregnancy in Women with Moderate–severe Inflammatory Bowel Disease and the Risk of Preterm Birth and Low Birth Weight

Conclusions: For anti–TNF-α therapy in the third trimester, we found no statistically significant increased risk of either LBW or preterm birth.
Source: Inflammatory Bowel Diseases - Category: Gastroenterology Tags: IBD LIVE Articles Source Type: research